PMID- 11267943
OWN - NLM
STAT- MEDLINE
DCOM- 20010712
LR  - 20190513
IS  - 0910-5050 (Print)
IS  - 1876-4673 (Electronic)
IS  - 0910-5050 (Linking)
VI  - 92
IP  - 3
DP  - 2001 Mar
TI  - Efficient gene transduction by RGD-fiber modified recombinant adenovirus into 
      dendritic cells.
PG  - 321-7
AB  - Dendritic cells (DC) are important antigen-presenting cells in the development of 
      an anti-tumor T cell response. To extend the range of current immuno / gene 
      therapies, we tested luciferase-expressing RGD-adenovirus (Ad) 
      (Ad5lucRGD)-mediated transduction into DC. Phenotypically characterized DC were 
      generated from peripheral blood CD14(+) cells by incubation with 
      granulocyte-macrophage colony-stimulating factor, interleukin-4 and tumor 
      necrosis factor alpha. On the 7th day of culture, the cells became mature DC with 
      a CD1a(+), CD11c(+), CD80(+), CD83(+), CD86(+), human leukocyte antigen 
      (HLA)-DR(+), CD14- phenotype. The expression of alpha( v)beta(3) integrin was 
      enhanced on day 3 and returned to the basal level on day 7. We then compared the 
      transduction efficiency of an Ad5lucRGD system to that using conventional Ad, in 
      cells harvested on days 1, 3 and 7 of culture. Luciferase activity was negligible 
      in AdCMVLuc, but remarkable in cells processed with Ad5lucRGD. Activity was 
      maximal in cells that had been cultured for 3 days. Recombinant Ad5 fiber knob 
      protein blocked AdCMVLuc- and Ad5lucRGD-mediated gene transduction by 90% and 
      20%, respectively. Surface markers and cytokine production were not affected by 
      Ad5lucRGD-mediated transduction.
FAU - Asada-Mikami, R
AU  - Asada-Mikami R
AD  - Pharmacology Division, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, 
      Japan.
FAU - Heike, Y
AU  - Heike Y
FAU - Kanai, S
AU  - Kanai S
FAU - Azuma, M
AU  - Azuma M
FAU - Shirakawa, K
AU  - Shirakawa K
FAU - Takaue, Y
AU  - Takaue Y
FAU - Krasnykh, V
AU  - Krasnykh V
FAU - Curiel, D T
AU  - Curiel DT
FAU - Terada, M
AU  - Terada M
FAU - Abe, T
AU  - Abe T
FAU - Wakasugi, H
AU  - Wakasugi H
LA  - eng
GR  - N01 CO97110/CO/NCI NIH HHS/United States
GR  - R01 CA74242/CA/NCI NIH HHS/United States
GR  - R01 CA86881/CA/NCI NIH HHS/United States
GR  - R01 HL50255/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Japan
TA  - Jpn J Cancer Res
JT  - Japanese journal of cancer research : Gann
JID - 8509412
RN  - 0 (Antigens, CD)
RN  - 0 (Integrins)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Oligopeptides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 78VO7F77PN (arginyl-glycyl-aspartic acid)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EC 1.13.12.- (Luciferases)
SB  - IM
MH  - Adenoviridae/*genetics
MH  - Amino Acid Sequence
MH  - Antigens, CD/analysis
MH  - Cell Culture Techniques/methods
MH  - Cells, Cultured
MH  - Dendritic Cells/*cytology/drug effects/immunology
MH  - Flow Cytometry
MH  - Genes, Reporter
MH  - Genetic Vectors
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Immunophenotyping
MH  - Integrins/analysis
MH  - Interleukin-4/pharmacology
MH  - Lipopolysaccharide Receptors/analysis
MH  - Luciferases/analysis/*genetics
MH  - Lung Neoplasms
MH  - Oligopeptides
MH  - Transfection/methods
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/pharmacology
PMC - PMC5926705
EDAT- 2001/03/27 10:00
MHDA- 2001/07/13 10:01
PMCR- 2001/03/01
CRDT- 2001/03/27 10:00
PHST- 2001/03/27 10:00 [pubmed]
PHST- 2001/07/13 10:01 [medline]
PHST- 2001/03/27 10:00 [entrez]
PHST- 2001/03/01 00:00 [pmc-release]
AID - CAE321 [pii]
AID - 10.1111/j.1349-7006.2001.tb01098.x [doi]
PST - ppublish
SO  - Jpn J Cancer Res. 2001 Mar;92(3):321-7. doi: 10.1111/j.1349-7006.2001.tb01098.x.